Meeting Minutes

Date: Wednesday, May 20, 2015
Time: 10:00 AM – 12:00 PM

Location: Health Sciences Building T-269

Members Present:
1. Michael Agy, Washington National Primate Research Center
2. Thea Brabb, Comparative Medicine (Animal Containment Expert)
3. H.D. “Toby” Bradshaw, Biology (Plant Expert)
4. Lesley Colby, Comparative Medicine (Animal Containment Expert)
5. Elizabeth Corwin (Human Gene Transfer Expert; IBC Vice Chair)
6. Jean Haulman, UW Travel Clinic
7. David Koelle, Allergy and Infectious Diseases
8. Stephen Libby, Laboratory Medicine (IBC Chair)
9. Jeanot Muster, Pharmacology
10. Angela Rasmussen, Microbiology
11. Eric Stefansson, Environmental Health & Safety (Biosafety Officer)
12. Paul Swenson, Seattle-King Co. Dept. of Public Health (Community Member)
1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 am. A quorum was present.

2. **REMEMBER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.

3. **APPROVAL OF MINUTES:**
   - The IBC Chair sought a motion to approve the minutes from the April 15, 2015 minutes meeting.
   - A member made a motion to approve the April 15, 2015 minutes. Another member seconded the motion.
   - The committee voted unanimously to approve the April 15, 2015 meeting minutes.

4. **BIOSAFETY OFFICER (BSO) REPORT:** The BSO report is for projects involving non-recombinant infectious agents and projects falling under Section III-E and III-F of the *NIH Guidelines*. Administrative updates, such as room additions, are also included here.

   **Biosafety Officer Report**
   - Dr. Lukehart added non-human primate source material for use in rabbits and in-vitro.
   - A discussion occurred regarding import permits. Dr. Lukehart has an import permit from the CDC (Centers for Disease Control and Prevention) for the non-human primate source material.
   - A discussion occurred regarding the biosafety level of *Staphylococcus epidermidis*. This agent is worked with at BSL-1 (biosafety level 1).
   - One member declared a conflict of interest.
   - The IBC Chair sought a motion to approve this month’s Biosafety Officer Report.
   - A member made a motion to approve this month’s Biosafety Officer Report. Another member seconded the motion.
   - The Committee unanimously voted, with one recusal, to approve this month’s Biosafety Officer Report.

5. **INDIVIDUAL PROJECT REVIEWS**

   1. **Froehner, Stanley, renewal, Froehner Muscular Dystrophy Projects**
      - The assigned IBC Primary Reviewer presented the Primary Review.
      - The overall goals of the research are to understand muscle function and the causes of muscle disease, and to test potential therapies.
      - AAV (adeno-associated viral vectors) will be used in mice.
      - The draft BUA (Biological Use Authorization) letter was shown.
      - The lab is creating transgenic mice. This will be added to the letter.
      - The lab inspection has been completed, and they are up-to-date on their training.
      - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Froehner. A second is not needed since he is the Primary Reviewer.
      - The Committee voted unanimously to approve the draft BUA for Dr. Froehner, contingent upon adding creation of transgenic mice to the BUA letter.
2. Hu, Shiu-Lok, renewal, *Macaque model to validate the significance of a V1/V2-based vaccine toward protection against HIV-1 infection.*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The lab studies HIV and works to contribute to the design of more effective HIV vaccines.
   - Biohazardous agents used on this project include SHIV (simian-human immunodeficiency virus), which is administered to macaques. Human and non-human primate blood and cell lines are also used.
   - The lab has been inspected, and the training has been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Hu. A second is not needed since he is the Primary Reviewer.
   - The Committee voted unanimously to approve the draft BUA for Dr. Hu.

3. Katze, Michael, renewal, *Genomic, Proteomic, and Metabolomic Profiling of Hepatitis C Virus-Infected Cultured Cells*
   - One member declared a conflict of interest.
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - A question was raised about Dengue virus. Working with more than one strain of Dengue virus can pose a serious hazard to the researchers working on this project. The researchers have received occupational health information and will be working with only one strain of the virus.
   - Other biohazardous agents used include poliovirus, Hepatitis C, Sendai virus, and lentiviral vectors. No animals are used on this project.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Katze. A second is not needed since he is the Primary Reviewer.
   - The Committee voted unanimously, with one recusal, to approve the draft BUA for Dr. Katze.

4. Kerr, Benjamin, new, *The Evolution of Cooperation by the Hankshaw Effect*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The lab studies the evolution of cooperation.
   - *Pseudomonas aeruginosa* is used on the project.
   - The lab has been inspected, and the training has been completed.
   - The draft BUA letter was shown.
   - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Kerr. A second is not needed since he is the Primary Reviewer.
   - The Committee voted unanimously to approve the draft BUA for Dr. Kerr.

5. Ladiges, Warren, renewal, *Cancer Consortium Xenograft Resource*
   - The assigned IBC Primary Reviewer presented the Primary Review.
   - The lab uses transfected human cells in mice.
   - The draft BUA letter was shown.
   - Some minor deficiencies were noted during the lab inspection, but they have since been corrected.
   - Question 54 on the BUA application was left unchecked.
• The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ladiges. A second is not needed since he is the Primary Reviewer.
• The Committee voted unanimously to approve the draft BUA for Dr. Ladiges, pending completion of question 54 on the BUA application.

   • The assigned IBC Primary Reviewer presented the Primary Review.
   • The lab studies a phenomenon known as replication-transcription conflicts, collisions between the DNA replication machinery and the transcription machinery in bacteria. These are known to cause mutations and are generally deleterious to cell viability.
   • *Staphylococcus aureus, Listeria monocytogenes, Bacillus cereus,* and *Bacillus thuringiensis* are used on this project.
   • The draft BUA letter was shown.
   • The lab has been inspected and there are a few minor corrections that need to be made. The training has been completed.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Merrikh. A second is not needed since he is the Primary Reviewer.
   • The Committee voted unanimously to approve the draft BUA for Dr. Merrikh, contingent upon correction of lab inspection deficiencies.

7. Schwartz, Michael, change, *Neuroendocrine Control of Energy Balance*
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • This is a change to add LCMV (lymphocytic choriomeningitis virus), used both in vitro and in mice. The principal investigator originally classified the LCMV as recombinant. However, later communication with the PI revealed that it is not actually recombinant.
   • The draft BUA letter was shown.
   • The Primary Review mentions that a room needs to be removed from the BUA letter. The rooms are now correctly listed on the BUA letter.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Schwartz. A second is not needed since she is the Primary Reviewer.
   • The Committee voted unanimously to approve the draft BUA for Dr. Schwartz.

8. Woodward, Joshua, new, *Probiotic mediated treatment of metabolic and immune disorders*
   • The assigned IBC Primary Reviewer presented the Primary Review.
   • The investigator is developing probiotic bacteria that specifically target small molecule activated transcription factors, for therapeutic use in treating autoimmune, metabolic, and developmental diseases.
   • A variety of Risk Group 1 probiotic bacteria, including *Lactobacillus acidophilus* and *Streptococcus thermophilus,* will be used on this project. Human cells will also be used.
   • The lab has recently been inspected, and training has been completed.
   • The draft BUA letter was shown.
   • The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Woodward. A second is not needed since she is the Primary Reviewer.
   • The Committee voted unanimously to approve the draft BUA for Dr. Woodward.
SUBCOMMITTEE REPORTS:

9. Woolfrey, Ann, new, Phase I/II study of CaspaCide T cells from an HLA-partially matched family donor after negative selection of TCR αβ +T cells in pediatric patients affected by hematological disorders
   - Three members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
   - The goal of the research is to investigate whether transduction of T cells carrying an inducible suicide gene after a haploidentical (half-matched) stem cell transplant will be effective, while minimizing the risks associated with haploidentical stem cell transplants.
   - A gammaretroviral vector will be used. This will be administered to research participants at UW Medical Center.
   - Candidates for the study have malignant or severe non-malignant bone marrow disorders requiring a stem cell transplant. Participants in this study are only eligible if an HLA identical donor cannot be found, but an HLA haploidentical matched relative has been identified.
   - The RAC (Recombinant DNA Advisory Committee) performed an initial review, but determined that a more in-depth review was not required.
   - The subcommittee also reviewed the proposed consent forms, the clinical protocol, and the investigator’s brochure.
   - The draft BUA letter was shown.
   - A member made a motion to approve the draft BUA letter for Dr. Woolfrey. Another member seconded the motion.
   - The Committee voted unanimously to approve the draft BUA for Dr. Woolfrey.

ADMINISTRATIVE UPDATES:

- The DURC IRE (Dual Use Research of Concern Institutional Review Entity) has formed and the first meeting took place last week. The SAGE ecg1 questions are in the process of being updated as a way to screen for DURC research. The BUA application will also be updated.
- The committee watched a short video about DURC.

FOR YOUR INFORMATION:

- Future IBC meetings will be held in a larger room, Foege N130A. Instructions about how to get there will be sent before the June meeting.

ISSUES FROM THE FLOOR & PUBLIC COMMENTS:
There were no issues from the floor, and no public comments.

MEETING ADJOURNED AT APPROXIMATELY 11:30 a.m.